[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM: Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res; 2006 Mar 1;12(5):1540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
  • PURPOSE: A phase I trial of intrathecal Spartaject Busulfan (SuperGen, Inc., San Ramon, CA) was conducted in children with neoplastic meningitis following recurrent primary brain tumors to describe toxicities, estimate the maximum tolerated dose (MTD), and document evidence of responses to this agent.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Meningeal Neoplasms / drug therapy. Meningitis / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Choroid Plexus Neoplasms / blood. Choroid Plexus Neoplasms / cerebrospinal fluid. Choroid Plexus Neoplasms / drug therapy. Cohort Studies. Ependymoma / blood. Ependymoma / cerebrospinal fluid. Ependymoma / drug therapy. Female. Glioma / blood. Glioma / cerebrospinal fluid. Glioma / drug therapy. Humans. Injections, Spinal. Male. Maximum Tolerated Dose. Neuroectodermal Tumors, Primitive / blood. Neuroectodermal Tumors, Primitive / cerebrospinal fluid. Neuroectodermal Tumors, Primitive / drug therapy

  • MedlinePlus Health Information. consumer health - Meningitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533779.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U01 CA081457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan
  •  go-up   go-down


2. Lozier AP, Arbaje YM, Scheithauer BW: Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report. Neurosurgery; 2009 Oct;65(4):E816-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report.
  • OBJECTIVE: Choroid plexus carcinoma (CPCa) is an uncommon tumor rarely occurring in patients older than 2 years of age.
  • The case reported herein represents the first documented example of a primary supratentorial, extraventricular CPCa in an adult.
  • INTERVENTION: The tumor was gross-totally removed via a frontotemporal craniotomy.
  • A magnetic resonance imaging scan 44 months after surgery showed no evidence of residual or recurrent tumor.
  • [MeSH-major] Carcinoma / pathology. Choroid Plexus / pathology. Choroid Plexus Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Brain / physiopathology. Brain / surgery. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Administration Schedule. Female. Humans. Lateral Ventricles / pathology. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834361.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T, Pediatric Brain Tumor Consortium: Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer; 2009 Feb;52(2):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase I dose escalation study stratified by concurrent use (stratum II) or absence (stratum I) of enzyme-inducing anticonvulsant drugs was undertaken to estimate the maximum-tolerated dose (MTD) and to describe the toxicity profile of SU5416 in pediatric patients with refractory brain tumors.
  • Tumor types included 23 glial tumors, 4 neural tumors, 4 ependymomas, and 2 choroid plexus carcinomas.
  • The most serious drug-related toxicities were grade 3 liver enzyme abnormalities, arthralgia, and hallucinations.
  • The plasma pharmacokinetics of SU5416 was not significantly affected by the concurrent administration of enzyme-inducing anticonvulsant drugs.
  • The plasma pharmacokinetics of SU5416 in children was similar to previously reported findings in adult cancer patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2798-805 [12231519.001]
  • [Cites] Neoplasia. 2003 Mar-Apr;5(2):155-60 [12659688.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jun;305(3):833-9 [12626639.001]
  • [Cites] Cell Mol Life Sci. 2003 Apr;60(4):794-802 [12785726.001]
  • [Cites] Am J Ophthalmol. 2003 Jul;136(1):194-6 [12834696.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Blood. 2003 Aug 1;102(3):795-801 [12649163.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2763-7 [12843001.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4772-81 [14581348.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jan;53(1):39-42 [14551735.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):88-95 [14734456.001]
  • [Cites] Oncol Res. 2004;14(4-5):175-225 [14977353.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3365-70 [15161690.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4048-54 [15217937.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):193-6 [15271314.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5732-40 [15355900.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80 [15474452.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1174-80 [15305185.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):99-106 [9892193.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1261-6 [9815808.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):283-91 [15541812.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Mar;55(3):295-300 [15538570.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):876-83 [16222321.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):109-15 [16601426.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):423-31 [16477628.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2601-9 [17169805.001]
  • [Cites] Drug Metab Dispos. 2000 Dec;28(12):1505-12 [11095590.001]
  • [Cites] Blood. 2001 Jul 1;98(1):241-3 [11418488.001]
  • [Cites] Kobe J Med Sci. 2001 Aug;47(4):181-91 [11733657.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1657-67 [11896117.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1745-51 [12208726.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):165-72 [16983506.001]
  • (PMID = 19065567.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081457-07; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01 CA081457-07; United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anticonvulsants; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 71IA9S35AJ / Semaxinib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS124020; NLM/ PMC2775441
  •  go-up   go-down


Advertisement
4. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, McKhann GM, Goodman RR, Fine RL: Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol; 2006 Jan;76(1):85-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.
  • BACKGROUND: P-glycoprotein (Pgp) mediates, in part, resistance to natural product chemotherapy drugs which constitute over half of the available drugs for cancer treatment.
  • Tamoxifen (TAM) enhances intracellular deposition of natural product chemotherapy in human cell lines by inhibition of Pgp.
  • Pgp is highly expressed in the choroid plexus and is thought to be a key component of the blood-cerebrospinal fluid barrier (BCSFB).
  • METHODS: Ten patients with either primary or metastatic brain tumors were randomized to: paclitaxel alone (175 mg/m2/IV) or a course of TAM (160 mg/m2 PO BID on Days 1-5) followed by paclitaxel (175 mg/m2/IV on Day 5).
  • CONCLUSIONS: The trend towards lower paclitaxel CSF concentrations when given with TAM is consistent with the published finding that Pgp's localization in the endothelial cells of the choroid plexus works in an opposite direction and keeps drugs in the CSF.
  • Thus, agents which inhibit Pgp, such as TAM, may increase efflux of Pgp substrates out of the BCSFB and may paradoxically lower CSF concentrations of natural product chemotherapy drugs.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Phytogenic / cerebrospinal fluid. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / cerebrospinal fluid. Tamoxifen / pharmacology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chromatography, High Pressure Liquid. Female. Humans. Infusions, Intravenous. Male. Middle Aged. P-Glycoprotein / antagonists & inhibitors. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] J Chromatogr. 1992 Nov 6;582(1-2):273-8 [1362729.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):683-8 [12066192.001]
  • [Cites] Blood. 1991 Feb 15;77(4):818-25 [1993221.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):1022-30 [9041166.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2964-76 [9738565.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5 [10097135.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Biochem Pharmacol. 1998 Feb 15;55(4):523-31 [9514088.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81 [7616600.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1955-60 [9951847.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):101-8 [11550305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8 [2563168.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):287-92 [7914405.001]
  • [Cites] Arch Neurol. 1999 Jun;56(6):703-8 [10369310.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 15;202(1):606-12 [7913604.001]
  • [Cites] J Chromatogr. 1991 Apr 19;565(1-2):482-7 [1831461.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Br J Clin Pharmacol. 1997 Feb;43(2):189-93 [9131952.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1811-6 [1359155.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • (PMID = 16402278.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089395
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol; 2006 Feb;290(2):H560-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.
  • Unlike during development, blood vessels in the adult are generally thought not to require VEGF for normal function.
  • However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF.
  • In this study, we sought to identify which, if any, vascular beds in adult mice depend on VEGF for survival.
  • In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue.
  • Our findings of VEGF dependency of normal fenestrated capillaries and rapid regrowth after regression demonstrate the plasticity of the adult microvasculature.
  • [MeSH-minor] Animals. Blood Pressure. Carcinoma, Lewis Lung / blood supply. Glucose Tolerance Test. Heart / physiology. Imidazoles. Indazoles / pharmacology. Islets of Langerhans / blood supply. Kidney / physiology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Neoplasm Transplantation. Pancreatic Neoplasms / blood supply. Phenotype. Reference Values. Regeneration. Signal Transduction / drug effects. Signal Transduction / physiology. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H509-11 [16403945.001]
  • (PMID = 16172168.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / HL-59157; United States / NCI NIH HHS / CA / P50 CA-90270
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Indazoles; 0 / Vascular Endothelial Growth Factor A; C9LVQ0YUXG / axitinib; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down






Advertisement